Prime Medicine, Inc.
PRME- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001894562
No open-market purchases or sales by Prime Medicine, Inc. insiders were filed in the last 90 days; 187 institutions reported holding it in 13F filings for Q2 2026, worth $393.5M in total; ARK Invest is the only superinvestor holding it.
Holders of 5% or more of PRME
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Prime Medicine, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| GV 2019, L.P. | 13G/A | 12.30%16.6M shares | – | Nov 12, 20251 filing | Nov 12, 2025 | SEC |
| ARCH Venture Fund XII, L.P. | 13D/A | 10.40%18.6M shares | – | Aug 11, 20251 filing | Aug 11, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
6 Schedule 13D and 13G filings on Prime Medicine, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 202610:28 AM ET | T. Rowe Price Investment Management, Inc. | 13G/A | 3.30%6.00M shares | −2.00 ppfrom 5.30%Below 5% | Dec 31, 2025 | SEC |
| Nov 14, 202512:18 PM ET | T. Rowe Price Investment Management, Inc. | 13G | 5.30%9.24M shares | New | Sep 30, 2025 | SEC |
| Nov 12, 20254:30 PM ET | GV 2019, L.P.and 11 others | 13G/A | 12.30%16.6M shares | – | Sep 30, 2025 | SEC |
| Nov 5, 202511:44 AM ET | FMR LLCand 1 other | 13G/A | 3.80%6.73M shares | –Below 5% | Sep 30, 2025 | SEC |
| Aug 11, 20259:48 PM ET | ARCH Venture Fund XII, L.P.and 11 others | 13D/A | 10.40%18.6M shares | – | Aug 7, 2025 | SEC |
| Feb 14, 20254:15 PM ET | Newpath Partners, L.P.and 3 others | 13G/A | 4.70%6.11M shares | –Below 5% | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Prime Medicine, Inc. shares.
No Form 144 notices for Prime Medicine, Inc. are on file.